triazoles has been researched along with tak 603 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (66.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, A; Fukuda, S; Makino, H; Nagai, H; Ohta, Y; Sohda, T; Tsukuda, R | 1 |
| Makino, H; Ohta, Y; Sohda, T; Yamane, M | 1 |
| Fukuda, S; Makino, H; Ohta, Y | 1 |
| Baba, A; Makino, H; Ohta, Y; Sohda, T | 1 |
| Hagimoto, T; Motohashi, M; Okada, J; Yoshimura, Y | 1 |
| Kiyota, Y; Motohashi, M; Tagawa, Y; Tanayama, S; Yoshimura, Y | 1 |
| Miwa, K; Tagawa, Y; Tanayama, S; Tanigawara, Y; Tsukuda, R; Yamashita, K; Yoshimura, Y | 1 |
| Miwa, K; Tagawa, Y; Tanayama, S; Tanigawara, Y; Tsukuda, R; Yoshimura, Y | 1 |
| Baba, A; Makino, H; Nishimura, A; Notoya, K; Oda, T; Sohda, T; Taketomi, S | 1 |
| Baba, A; Makino, H; Mori, A; Sohda, T; Unno, S; Yasuma, T | 1 |
| Akiyama, T; Fujimi, A; Hirayama, Y; Kato, J; Kogawa, K; Kon, S; Konuma, Y; Kuroda, H; Kusakabe, T; Lu, Y; Matsunaga, T; Niitsu, Y; Nishiie, K; Sakamaki, S; Takemoto, N | 1 |
| Ezoe, K; Fujita, T; Homma, K; Jimbow, K; Matsumoto, Y; Saito, T; Sato, N | 1 |
| Abe, S; Hiraga, Y; Sato, N; Shigehara, K; Shijubo, N; Takahashi, R | 1 |
| Furuichi, K; Kaneko, S; Sakai, N; Wada, T; Yamahana, J; Yokoyama, H | 1 |
| Albring, J; Berdel, WE; Bisping, G; Kiehl, M; Kienast, J; Opitz, C; Pauels, HG; Poremba, C; Scheffold, C; Schlösser, V; Silling, G; Specht, C; Stelljes, M; Volkmann, S | 1 |
1 trial(s) available for triazoles and tak 603
| Article | Year |
|---|---|
Double column-switching high-performance liquid chromatographic method for the determination of TAK-603 and its metabolites in human serum.
Topics: Administration, Oral; Antirheumatic Agents; Chromatography, High Pressure Liquid; Drug Stability; Humans; Male; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Triazoles | 1998 |
14 other study(ies) available for triazoles and tak 603
| Article | Year |
|---|---|
Immunomodulating and articular protecting activities of a new anti-rheumatic drug, TAK-603.
Topics: Adjuvants, Immunologic; Animals; Antirheumatic Agents; Arthritis, Experimental; Autoimmune Diseases; Cartilage; Cells, Cultured; Cytokines; Dinoprostone; Extracellular Matrix; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Quinolines; Rabbits; Radiography; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Spleen; Triazoles | 1996 |
TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cell Culture Techniques; Cytokines; Dose-Response Relationship, Drug; Gene Expression; Male; Mice; Mice, Inbred A; Mice, Inbred BALB C; Ovalbumin; Quinolines; Rats; Rats, Inbred Lew; RNA, Messenger; Th1 Cells; Triazoles | 1997 |
Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Autoimmune Diseases; CD4-CD8 Ratio; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Lymphocyte Subsets; Male; Quinolines; Rats; Rats, Inbred Lew; Spleen; T-Lymphocytes; Triazoles | 1997 |
Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quino line-3-carboxylate (TAK-603).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Biotransformation; Cell Division; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Quinolines; Rats; Rats, Inbred Lew; Spleen; Triazoles | 1998 |
Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Bile; Blood Cells; Blood Proteins; Cartilage, Articular; Dogs; Injections, Intravenous; Joints; Male; Protein Binding; Quinolines; Rats; Rats, Wistar; Species Specificity; Synovial Fluid; Tissue Distribution; Triazoles | 1998 |
Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Injections, Intravenous; Male; Metabolic Clearance Rate; Microsomes, Liver; Models, Biological; Nifedipine; Nonlinear Dynamics; Oxidation-Reduction; Quinolines; Rats; Rats, Wistar; Tissue Distribution; Tocolytic Agents; Triazoles | 1999 |
Effect of its demethylated metabolite on the pharmacokinetics of unchanged TAK-603, a new antirheumatic agent, in rats.
Topics: Animals; Antirheumatic Agents; Bile Ducts; Blood Proteins; Catheterization; Dose-Response Relationship, Drug; Infusions, Intravenous; Kinetics; Male; Methylation; Protein Binding; Quinolines; Rats; Rats, Wistar; Triazoles | 1999 |
Studies on disease-modifying antirheumatic drugs. III. Bone resorption inhibitory effects of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl) quinoline-3-carboxylate (TAK-603) and related compounds.
Topics: Animals; Antirheumatic Agents; Bone and Bones; Bone Resorption; Calcium Radioisotopes; Female; Mice; Mice, Inbred C3H; Mice, Inbred ICR; Organ Culture Techniques; Osteoclasts; Ovariectomy; Quinolines; Rats; Rats, Sprague-Dawley; Triazoles | 1999 |
Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno[2,3-b:5,4-c']dipyridine derivatives and their anti-inflammatory effect.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Foot; Magnetic Resonance Spectroscopy; Male; Pyridines; Quinolines; Rats; Rats, Inbred Lew; Structure-Activity Relationship; Triazoles | 1999 |
Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603.
Topics: Acute Disease; Administration, Oral; Animals; Bone Marrow Transplantation; Cytokines; Drug Evaluation, Preclinical; Female; Graft vs Host Disease; Immunosuppressive Agents; Intestines; Liver; Lymphocyte Count; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Quinolines; Radiation Chimera; Skin; Spleen; Th1 Cells; Transplantation, Homologous; Triazoles | 2001 |
TAK-603, new rheumatic drug, inhibits rat mixed lymphocyte reactions and prolonges rat skin allograft survival.
Topics: Animals; Antirheumatic Agents; Graft Survival; Lymphocyte Culture Test, Mixed; Quinolines; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Skin Transplantation; Transplantation, Homologous; Triazoles | 2002 |
T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients.
Topics: Adult; Case-Control Studies; Female; Humans; Inflammation; Interferon-gamma; Interleukin-12; Interleukin-18; Leukocytes, Mononuclear; Male; Middle Aged; Quinolines; Sarcoidosis; T-Lymphocytes; Triazoles | 2004 |
TAK-603, an anti-inflammatory compound, reduces crescentic glomerulonephritis and preserves renal function in WKY rats.
Topics: Animals; Anti-Inflammatory Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Creatinine; Cytokines; Glomerulonephritis; Kidney; Kidney Glomerulus; Lymphocyte Count; Male; Microscopy, Electron, Transmission; Proteinuria; Quinolines; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Th1 Cells; Th2 Cells; Time Factors; Triazoles | 2006 |
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Topics: Animals; Antigens, Neoplasm; Cell Proliferation; Cytokines; Graft vs Host Disease; Graft vs Tumor Effect; Isoantigens; Mice; Mice, Inbred Strains; Quinolines; Th1 Cells; Triazoles; Tumor Cells, Cultured | 2007 |